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ABSTRACT 
Acinetobacter baumannii is an opportun-
istic nosocomial pathogen and one of the 
six most important multidrug-resistant 
microorganisms in intensive care units 
(ICU). 
The aim of this study was to determine the 
prevalence of antimicrobial resistant A. 
baumannii strains in ICU. 
We analysed antibiotic susceptibility of A. 
baumannii isolates collected in University 
Hospital Centre Zagreb over a four-year 
period (2011-2014) based on the hospital 
computer system data (BIS). The data were 
interpreted according to Clinical and Lab-
oratory Standards Institute criteria.
All strains from 2014 were found to be 
resistant to meropenem, which is a sig-
nificant increase when compared to 1.4% 
in 2011 and 81.8% in 2012. The resistance 
rate to imipenem increased to 95.8% in 
2014 from 91.4% in 2011 and 81.8% in 
2012. Colistin resistance, confirmed by E 
test, was found only in one strain in 2013. 
The resistance rates of other antimicrobial 
agents were as follows: ampicillin/sulbac-
tam 8.6% and 73.9%, netilmicin 70.6% and 
83.3%, gentamicin 48.6% and 91.7%, ami-
kacin 82.4% and 80.0% and ciprofloxacin 
100% and 100% in 2011 and 2014 respec-
tively.
Our data confirmed a multidrug-resist-
ance phenotype in Acinetobacter bauman-
nii strains isolated in ICU at the Clinical 
Hospital Centre, with a significant increase 
in resistance rates between 2011 and 2014 
against certain antimicrobial agents in-
cluding ampicilin/sulbactam and carbap-
enems. 
Key words: Acinetobacter baumannii, mul-
tidrug resistance, extensively drug resist-
ance, nosocomial pathogen
INTRODUCTION
Acinetobacter spp. are glucose non-fer-
menting, non-motile, catalase positive, 
and oxidase negative aerobic gram-neg-
ative cocobacilli. (1) The most important 
species in human medicine is Acinetobac-
ter baumannii. It is nowadays the leading 
causative agent of health care associated 
infections and is often called Gram-neg-
ative MRSA. (2) Health care associated 
infections tend to occur in debilitated pa-
tients in intensive care units (both children 
and adults) and among residents of long-
term care facilities (particulary facilities 
caring for ventilator-dependent patients). 
Additional risk factors include recent sur-
gery, central vascular catheterization, tra-
cheostomy, mechanical ventilation, enteral 
feedings, and treatment with third genera-
tion cephalosporin, fluoroquinolones, or 
carbapenem antibiotics. (1,3) It has a great 
capacity of acquiring resistance traits and 
spreading within the hospital environ-
ment. Many factors contributed to the vir-
ulence of Acinetobacter species: survival 
in dry and iron-deficient conditions for a 
long period of time, the production of a 
polysaccharide capsule that works with the 
cell wall liposaccharide to prevent com-
plement activation. The capsule prevents 
phagocytosis and enables the survival of 
bacteria in the blood. Colonisation in the 
lung is facilitated by the ability of Acineto-
bacter to adhere to human bronchial epi-
thelial cells using fimbriae. (4) In addition, 
the colonization of environmental surfaces 
is promoted by adhesion via pili and the 
subsequent formation of biofilm. Most A. 
baumannii isolates are highly resistant to 
most antibiotics available in clinical prac-
tice due to intrinsic and acquired resist-
ance mechanisms. A number of resistance 
mechanisms to many classes of antibiotics 
are known to exist in A. baumanni, includ-
ing β-lactamases production (particu-
larly carbapenemases), upregulated efflux 
pumps, production of aminoglycoside-
modifying enzymes, permeability defects 
and the alteration of target sites. (1) The 
spread of multidrug resistance determi-
nants in A. baumannii occurs by conjuga-
tion, transposon acquisition or integron 
mobilization to gain clusters of genes en-
coding resistance to several antibiotics 
families.(5)
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The aim was to analyze the prevalence and 
antibiotic sensitivity patterns of Acineto-
bacter baumannii isolates from patients 
hospitalized at the Department for Inten-
sive Care Medicine, University Hospital 
Centre Zagreb. The number and the type 
of microbiological specimens with A. bau-
mannii were determined as well. 
 MATERIAL AND METHODS
The data are based on a retrospective study 
conducted between 1 January 2011 and 31 
December 2014. The data were collected 
from the hospital computer system (BIS). 
Only one isolate per patient was included 
in the study. Antibiotic susceptibility was 
determined according to EUCAST guide-
lines (European Committee on Antimicro-
bial Susceptibility Testing). The general pa-
rameters of ICU (number of beds, number 
of patients and the total number of bacte-
riological results) were used to calculate 
the resistance rates and the proportion of 
A. baumannii in the total number of posi-
tive bacteriological results. 
RESULTS
The Department for Intensive Care Medi-
cine has 12 beds. The total number of pa-
tients hospitalized in the department in the 
study period (2011-2014) was as follows: 
589, 590, 590, 562 , while the number of 
patients  with A. baumannii isolates was 
50, 20, 47, 37 in 2011, 2012, 2013 and 2014 
respectively (table 1.). The largest number 
of A. baumannii isolates originated from 
respiratory tract specimens (tracheal as-
pirate, BAL, minilavate) during the whole 
four-year study period (figure 1).
Resistance rates for meropenem ranged 
from 81.8 % (2012) to 100% (2014). Simi-
larly, imipenem showed the resistance rate 
which increased from 81.8% in 2011 to 
95.8% in 2014. The highest increase of the 
resistance rate was observed for ampicilin/
sulbactam from 8.6% in 2012 to 73.9% in 
2014 and for gentamicin with the range 
from 48.6% in 2011 to 91.7%. in 2014. No 
resistance rate to colistin was observed, 
except for one single strain (figure 2). The 
resistance rates to amikacin and cipro-
floxacin did not change during the study 
period. 
Figure 1. The proportion of A. baumannii 
isolates from various clinical samples
Blood c.= Blood culture, 
i.v. cat.= intravascular catether samples
Resp. s. = respiratory samples, 
Surv. c.= surveillancy culture, 
UC= urine culture 
Figure 2. Percentage of  A. baumannii 
strains resistant to various antibiotics over 










In our study A. baumannii was isolated in 
9-17.2 % of all bacteriological specimens, 
which is comparable to Prashanth et al. 
with 10% Acinetobacter isolates (6), Path-
wardhan et al. with 13-23% (7) and Purti et 
al. with 11.96% .(8) The most common site 
for A. baumannii infection is the respira-
tory tract and the most common manifes-
tation is VAP (9). This is in concordance 
with the high number of isolates from the 
respiratory tract and blood cultures in our 
study. The ability of Acinetobacter strains 
to adhere to the surface is an important 
mechanism in pathogenicity. It frequently 
causes infections associated with medi-
cal devices, e.g. vascular catheters. Bio-
film formation is a well-known virulence 
mechanism in such infections. (10) This 
explains a high number of strains from 
vascular catheter swabs and lavates. 
Analysis of susceptibility patterns showed 
that most isolates do not have only the 
multidrug-resistant phenotype (MDR) but 
also extensively drug-resistant phenotype 
(XDR). Proportion of XDR A. bauman-
nii in total number of MDR A. baumannii 
increased from 24% and 5% in 2011 and 
2012 to 40% and 70.2 % in 2013 and 2014. 
A similar proportion of XDR A. bauman-
nii of 72.4 % was reported in the study 
byMetan et al. at the bone marrow clinic. 
(11) The proportion of isolates resistant 
to carbapenems (imipenem, meropenem) 
in our ICU reached the peak level in 2014 
(100% resistant to meropenem, 95% to 
imipenem). Guven et al. reported in their 
study from 2011 the resistance rate to car-
bapenems of 98.9%, also in ICU. (12) The 
hospital in general demonstrated in 2014. 
a smaller resistance rate to carbapenems of 
87.8%, compared to ICU. On the national 
level, there was also an increase from 23% 
in 2009 to 80% in 2013 in Croatia. (13) 
Clinical studies showed higher mortal-
ity rates of patients infected with carbap-
enem-resistant strains compared to those 
infected with carbapenem-susceptible 
strains. (14, 15) An alarming increase of 
the resistance rate was reported for ampici-
lin/sulbactam from 8.6% in 2012 to 73.9% 
in 2014 in ICU. In the hospital in general 
the resistance rate for ampicillin/sulbac-
tam was 64%, while in the whole country 
the rate was 26%. No resistance to colistin 
was observed except in one single strain. 
At the University Hospital Centre the re-
sistance rate for colistin was 1.6%, which 
is slightly higher than at the national level 
in Croatia (1%). The first study on carbap-
enem resistance in A. baumannii at the 
University Hospital Centre Zagreb dem-
onstrated the emergence of OXA-72 beta-
lactamase belonging to OXA-24-like group 
among isolates from 2008. (16) 
CONCLUSION
The total number of A. baumannii in ICU 
was similar in each year during the study 
period, but the increase of resistance rates 
and the increased proportion of XDR A. 
baumannii compared to the total number of 
A. baumannii were observed. The increase 
of resistance rates to carbapenem and am-
picillin/sulbactam is worrisome. Early iden-
tification, effective strategies to control the 
use of antibiotics and continuous surveil-
lance and enforcement of specific infection 
control measures are strongly emphasized.
       SIGNA VITAE    |    15
Table 1. Epidemiological  parameters in ICU
Parameter 2011. 2012. 2013. 2014.
The number of patients with A. baumannii isolat 50 20 47 37
 Number/1000 bo  days ( ‰) 15,7 6,8 17,2 13,06
Number of microbiological specimens with A.baumannii isolate 69 48 96 62
% of total bacteriological specimens 13,5 9 17,2 11,2
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